This is for your blog, can you please post it for me?
CYTR is doing really interesting research - a novel approach to diabetes and obesity with RNA interference, and the stock is very cheap. I have more to write about CYTR but I don't have time now and it may be a good time to take a small position, in case it gets some more positive publicity.
CytRx Announces Publication of Major Article Demonstrating That Its Proprietary Drug Target RIP140 Controls Insulin Sensitivity and Glucose Tolerance
Thursday February 2, 8:30 am ET
Article Further Supports CytRx Approach to Therapeutic Treatment of Obesity and Type 2 Diabetes -
Note from A:
While we await Ilene's closer look at CYTR, here is what I see: Market Cap is $69M, cheap, cheap, cheap. They have 19 cents per share in cash and no debt. They are working on a treatment for obesity and diabetes, two huge markets. The publication of the article (above link) suggests they have something and it works. If that proves to be the case, then $69M is a fraction of what this company is really worth.